Progesterone After a Hysterectomy. Why the Conversation Is Changing.

If you have had a hysterectomy and started MHT, you probably have been prescribed oestrogen alone, with no progesterone.

The logic behind this is well established. Progesterone in MHT is added to protect the lining of the uterus from over-stimulation by oestrogen. No uterus, no lining, no need for progesterone. That has been the standard position for decades, it is consistent with current Australian guidelines, and for many women it is the right answer.

However, the most important exception is endometriosis. If your hysterectomy was for endometriosis, you may still have endometrial-type tissue elsewhere in your abdomen. That tissue can still be stimulated by oestrogen, which is why some women continue to need progesterone for protection. Whether this applies to you depends on why your hysterectomy was performed and what was advised at the time.

Beyond that exception, a growing conversation is starting to happen, in clinical research and increasingly in specialist menopause practice, about the roles progesterone has in the body beyond uterine protection. Roles in sleep. Mood. Brain. Bone. And possibly breast tissue.

This is an evolving area. The standard Australian position has not yet shifted, and may not shift for some time.

Sleep is where the strongest evidence sits. Waking at 2 or 3am, lying awake for hours, not being able to get back to sleep, then being so deeply asleep by the time the alarm goes off, this is unfortunately, incredibly common in menopause.

The reason is often multifactorial, but for many women, lower levels of progesterone can be the cause or the exacerbation. As a Former Registered Nurse and Clinical Myotherapist, and someone who reads beyond mainstream guidance, I am learning that this is one of the reasons specialists are now reconsidering the blanket position of not requiring progesterone, in order to help women get the sleep they need and want.

Why has progesterone been "for the uterus only"?

The standard logic for prescribing progesterone in MHT goes like this.

Oestrogen, given on its own to a woman with a uterus, can stimulate the uterine lining (the endometrium) to thicken. Over time, that thickening can progress to abnormal cell changes, and in some cases to endometrial cancer. Adding progesterone to the MHT regimen counteracts this by causing the lining to thin and shed, or in continuous combined regimens, by keeping the lining stable [1].

Women with a uterus on systemic oestrogen need progesterone, without exception. The body-identical option in Australia is micronised progesterone (Prometrium), taken as an oral capsule, or the Mirena IUD, which releases a low dose of synthetic progestogen directly into the uterus. Without a uterus, that protective role is not needed, and the standard position is oestrogen-only MHT.

Recent research is questioning whether progesterone might be doing other things in the body that have been overlooked because the uterus has dominated the conversation.

What do progesterone receptors do beyond the uterus?

Progesterone receptors are found in many tissues outside the uterus.

The brain has progesterone receptors in the hippocampus and prefrontal cortex, areas involved in memory, mood and cognition. Bone has progesterone receptors. Breast tissue has progesterone receptors. The cardiovascular system has progesterone receptors. Even the immune system shows progesterone receptor activity [2].

The presence of receptors does not by itself prove that supplementing progesterone benefits these tissues. It does, however, tell us that the body's own progesterone has biological roles beyond the uterus during the reproductive years. And it raises the question of whether replacing it after menopause has effects beyond endometrial protection.

This is the biological basis for the conversation that is currently growing.

What does the evidence say about progesterone and sleep?

The most well-supported claim for progesterone outside its uterine role is its effect on sleep.

Progesterone is metabolised in the body to a compound called allopregnanolone, which has a calming, sedating effect on the brain via the GABA receptor system [2].

Prometrium is generally taken at night, due to its ability to cause drowsiness for many women, with improved sleep often noticed within days of starting. The Australasian Menopause Society recognises this as a known clinical benefit of micronised progesterone alongside its endometrial protective role [3].

For women without a uterus, the question is different. Does that sleep benefit alone justify adding progesterone, given there is no endometrial protection role? This is where the standard position and the growing conversation diverge.

What about mood and the brain?

Progesterone's effect on mood, anxiety and brain function is less well-established. But it is an area of active research, and clinical opinion is shifting.

Some women, particularly those with a history of premenstrual mood symptoms, find their mood is more stable on micronised progesterone. Others find the opposite, with progesterone causing low mood. The individual response varies considerably and is not yet well predicted by clinical research.

The cognitive question is more uncertain. Progesterone receptors in the hippocampus and prefrontal cortex are well-documented, and animal studies suggest progesterone has neuroprotective effects. But high-quality randomised trials in postmenopausal women on the cognitive effects of progesterone replacement are limited. The evidence base is not yet strong enough to support a clinical recommendation either way.

What about bone?

Progesterone's effect on bone is at an earlier stage in the evidence pipeline than its effect on sleep.

There is some animal and laboratory evidence that progesterone may have a small role in bone formation, alongside oestrogen's much larger role in slowing bone resorption. There is no current Australian or international guideline that supports adding progesterone for bone protection in women without a uterus.

What about breast tissue?

Breast tissue is sometimes raised in this conversation, and the honest answer is that the evidence is limited.

There is no good-quality evidence that adding micronised progesterone to oestrogen-only MHT provides a protective effect on breast tissue in women without a uterus. Some authors have argued for a possible benefit, but the data does not yet support a confident position either way.

Where does the conversation diverge?

The standard Australian position, held by AMS, RANZCOG and Jean Hailes, is that progesterone is added to MHT for endometrial protection in women with a uterus. For women without a uterus, oestrogen-only therapy remains the standard, with no routine indication for adding progesterone [3,4,5].

A growing international conversation, particularly in specialist menopause practice, argues that progesterone has whole-body roles that justify considering it even in women without a uterus.

What does this mean for you?

If you have had a hysterectomy and are on oestrogen-only MHT and feeling well, there is no current clinical reason to change anything. The standard position is grounded in research. My view is that clinical practice and particularly guidelines takes time to evolve, they must assess pros and cons of new evidence as it emerges, but conversations in specialist menopause practice are now starting, feedback from women can be promising, it is an interesting concept to consider, and one I will continue to follow.

If you have had a hysterectomy and are on oestrogen-only MHT but are still struggling with sleep, persistent low mood, or anxiety symptoms that have not improved with oestrogen alone, this is a conversation worth having with your GP, particularly with one experienced in menopause. Adding micronised progesterone for sleep is an off-label use that some Australian menopause specialists will consider on an individual basis.

When women work with me, I will never tell them what to decide, however, I aim to help them see that the conversation is genuinely evolving, and that the answer should reflect your individual situation, current evidence, not simply a one-size-fits-all rule.

In simple terms

- Standard practice in Australia is oestrogen-only MHT for women without a uterus, because progesterone's main role in MHT is to protect the uterine lining.  

- The exception is hysterectomy for endometriosis, where residual tissue may still need progesterone protection.  

- Progesterone receptors exist in many tissues outside the uterus, including the brain, bone and breast.  

- The strongest evidence for a non-uterine role is sleep. Progesterone has a calming effect via the GABA system.  

- Adding micronised progesterone for sleep in women without a uterus is an off-label use considered by some Australian menopause specialists on an individual basis.  

- The standard Australian position has not yet shifted, but the conversation is open and worth bringing to your GP if it is relevant to you.

Want the complete picture?

There are three free resources to take this further.

Audio guide on progesterone after hysterectomy. A 10-minute audio overview in plain language. menopausehub.com.au/progesterone-audio (

Progesterone Key Fact Sheet. A one-page reference you can keep or take to your GP. menopausehub.com.au/links

MHT Complete Guide. The full plain-language guide. menopausehub.com.au/links

Next in the series

The next blog walks through how MHT is actually taken. Patches, gels, tablets, vaginal preparations, and pellets. The hormone is the same. The route changes more than you might expect.

Patches, Gels, Tablets, Vaginal, Pellets. Choosing How to Take MHT.

This information is educational only and does not constitute personal medical advice. Always consult a qualified health professional about your individual circumstances.

© 2026 Menopause Hub | Anna Pattison | Former Registered Nurse, Clinical Myotherapist, Menopause Mentor | menopausehub.com.au

CITATIONS

[1] Mirkin, S., et al. (2018). Micronised progesterone for endometrial protection: clinical perspectives. Climacteric, 21(4), 327-334.

[2] Schumacher, M., et al. (2014). Revisiting the roles of progesterone and allopregnanolone in the nervous system. Progress in Neurobiology, 113, 6-39.

[3] Australasian Menopause Society. Position Statement on Menopausal Hormone Therapy. menopause.org.au

[4] Australasian Menopause Society. Information Sheet — Progestogens and Bleeding. menopause.org.au

[5] Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Guidelines on Hormone Therapy. ranzcog.edu.au